Newell P., 2003, Biotech firms, biotech politics: Negotiating GMOs in India, The Journal of Environment Development, 16(2): 183-206Newell, P. 2003. Biotech firms, biotech politics: Negotiating GMOs in India. The Journal of Environment Development, 16(2): 183-206....
approval procedures, a lack of effective governmental oversight, poor corporate support for drug research, and differences in the treatment in China that are accorded to local and foreign firms. Nevertheless, China is reportedly expected to become the third-largestBiotechnologymarket in the world by ...
India represents the fastest-growing market in the Asia-Pacific region. The country's market growth is driven by increasing investments in biotechnology research, growing environmental awareness, and rising demand for sustainable products. India's strong agricultural base provides abundant feedstock for wh...
predictable activity. In the intensive care unit (ICU), sedation is essential to patient treatment. It has many uses in the intensive care unit, such as enabling invasive treatments, assisting with mechanical ventilation, and controlling agitation and anxiety. The increased desire for shorter hospital...
with an estimated value share of nearly 59% in 20212. According to Key Biotechnology Indicators collated by the Organisation for Economic Co-operation and Development (OECD), the country had by far the largest number of biotechnology firms in 2021 with 2,8403, though some sources say that numb...
The next two posts introduced three small oncology firms,CytRx ($CYTR),Threshold ($THLD)andZioPharm ($ZIOP). With $CYTR, I did not write anything useful about their current oncology pipeline, but they are developing INNO-206 for soft-tissue sarcoma, a cancer both $THLD and $ZIOP are ...
We Wish You a Happy New Year Filled with Excellent Health, Peace of Mind, Prosperity and Happiness What a Year for Biotechnology What happened in the biotech sector toward the end of 2019 is briefed in this Review as we focus on the performance of our picked firms’ stocks’ prices. We ...
This creates a bonanza for firms like mine that assist early, science-driven companies in managing their public positioning and their BD pitch from day one to create the largest possible exits. Now more than ever, the right story sells, just maybe to only one or two bidders. In Foundation’...
Unmatched Brand Exposure: Gain direct access to a global audience of scientists, clinicians, researchers, biotech firms, pharma leaders, and medical technology providers. Targeted Networking Opportunities: Engage with potential clients, investors, and top-tier professionals actively shaping the future of ...
Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains. A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities. ...